Noteworthy Price Action: Histogenics Corp Stock Price Declines Today

Noteworthy Price Action: Histogenics Corp Stock Price Declines Today

The stock of Histogenics Corp (NASDAQ:HSGX) is a huge mover today! The stock decreased 1.58% or $0.05 on October 3, hitting $3.11. About 80,397 shares traded hands or 118.98% up from the average. Histogenics Corp (NASDAQ:HSGX) has risen 10.32% since March 1, 2016 and is uptrending. It has underperformed by 1.90% the S&P500.
The move comes after 5 months negative chart setup for the $41.16M company. It was reported on Oct, 4 by Barchart.com. We have $2.71 PT which if reached, will make NASDAQ:HSGX worth $5.35M less.

Analysts await Histogenics Corp (NASDAQ:HSGX) to report earnings on November, 10.

Histogenics Corp (NASDAQ:HSGX) Ratings Coverage

Out of 5 analysts covering Histogenics Corp (NASDAQ:HSGX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Histogenics Corp has been the topic of 8 analyst reports since August 27, 2015 according to StockzIntelligence Inc. On Friday, November 13 the stock rating was downgraded by BTIG Research to “Neutral”. The firm has “Buy” rating given on Friday, August 12 by BTIG Research. The stock has “Market Perform” rating given by William Blair on Wednesday, September 7. Needham maintained it with “Buy” rating and $8 target price in Monday, September 19 report. The rating was maintained by Needham with “Buy” on Friday, November 13. The firm has “Hold” rating given on Thursday, August 27 by Zacks. The firm has “Buy” rating by Canaccord Genuity given on Friday, November 13.

According to Zacks Investment Research, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts.”

More important recent Histogenics Corp (NASDAQ:HSGX) news were published by: Globenewswire.com which released: “Histogenics Corporation Closes $30.0 Million Private Placement” on September 29, 2016, also Quotes.Wsj.com published article titled: “Histogenics Corp. HSGX (US: Nasdaq)”, Globenewswire.com published: “Histogenics Corporation Announces $30.0 Million Private Placement” on September 16, 2016. More interesting news about Histogenics Corp (NASDAQ:HSGX) was released by: Globenewswire.com and their article: “Histogenics Corporation Announces First Quarter 2016 Financial and Operating …” with publication date: May 12, 2016.

HSGX Company Profile

Histogenics Corporation, incorporated on July 14, 2006, is a regenerative medicine company. The Firm is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The Firm uses regenerative medicine platform to develop its products. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company’s TEP is designed to mimic the conditions found in a joint so that the implant is prepared to begin functioning like normal healthy cartilage prior to implantation. When NeoCart is implanted, a bioadhesive is used to anchor NeoCart in the cartilage injury and seal the implant to the surrounding native cartilage interface.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment